This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
Has DaVita (DVA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (DVA) Outperforming Other Medical Stocks This Year?
Surmodics Gets CE Mark for SurVeil Drug-Coated Balloon
by Zacks Equity Research
Surmodics' (SRDX) receipt of CE Mark for SurVeil DCB should boost the company's Medical Devices segment.
DexCom's (DXCM) G6 CGM System Gets CE Marking in Europe
by Zacks Equity Research
DexCom (DXCM) announces the receipt of CE Marking across Europe for its G6 CGM System.
5 Coronavirus-Proof PEG Picks Suitable for GARP Investors
by Urmimala Biswas
PEG-based investing can be more rewarding with the addition of a few other relevant parameters amid coronavirus-led market rattle.
Is DaVita HealthCare (DVA) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Is DaVita (DVA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (DVA) Outperforming Other Medical Stocks This Year?
Should Value Investors Buy DaVita HealthCare (DVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DVA vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Is DaVita (DVA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (DVA) Outperforming Other Medical Stocks This Year?
DaVita (DVA) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
DaVita's (DVA) dialysis services in the United States showcased solid results in Q1.
DaVita HealthCare (DVA) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 25.34% and 0.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for DaVita (DVA)This Earnings Season?
by Zacks Equity Research
DaVita (DVA) is expected to have gained from Kidney Care segment in Q1.
DaVita HealthCare (DVA) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: DaVita, EchoStar and PennyMac Financial Services
by Zacks Equity Research
Zacks.com featured highlights include: DaVita, EchoStar and PennyMac Financial Services
Should Value Investors Buy DaVita HealthCare (DVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Zacks Analyst Blog Highlights: InMode, Integer, Cardinal Health, DaVita and The Ensign Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: InMode, Integer, Cardinal Health, DaVita and The Ensign Group
3 Momentum Anomaly Stocks to Consider Amid Coronavirus Woes
by Zacks Equity Research
These fast movers are currently witnessing a short-term pullback in price as COVID-19 pandemonium batters market. So, this could essentially be a solid entry point for garnering profits.
5 Stocks to Buy for 5 Good Reasons
by Sejuti Banerjea
Here are 5 ways to make the most of a difficult market.
The Zacks Analyst Blog Highlights: DVA, CAH, TGNA, SLM and AMX
by Zacks Equity Research
The Zacks Analyst Blog Highlights: DVA, CAH, TGNA, SLM and AMX
Coronavirus-Led Volatility Rises: 5 High Earnings Yield Picks
by Zacks Equity Research
Dodge the COVID-19 pandemic by investing in these high earnings yield stocks.
5 Top Value Stocks to Buy in a Volatile April
by Nalak Das
Volatility is likely to persist in April as the panoptic impact of the coronavirus outbreak is yet to be realized in the United States and globally.
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Has DaVita (DVA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (DVA) Outperforming Other Medical Stocks This Year?
DaVita HealthCare (DVA) Stock Moves -0.46%: What You Should Know
by Zacks Equity Research
DaVita HealthCare (DVA) closed the most recent trading day at $76.06, moving -0.46% from the previous trading session.